Gyre Therapeutics (GYRE) Income towards Parent Company (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Income towards Parent Company data on file, last reported at -$9.9 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$9.9 million, down 364.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$23.3 million (down 126.28% YoY), and the FY2025 annual result was -$9.7 million, down 136.98% from the prior year.
• Income towards Parent Company climbed to -$9.9 million in Q1 2026 per GYRE's latest filing, from -$21.0 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $51.6 million in Q2 2022 and troughed at -$101.0 million in Q4 2023.
• A 5-year average of -$6.2 million and a median of $2.9 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2026: Income towards Parent Company surged 359.42% in 2022, then plunged 364.01% in 2026.
• A 5-year view of Income towards Parent Company shows it stood at -$27.9 million in 2022, then slumped by 261.95% to -$101.0 million in 2023, then soared by 78.77% to -$21.4 million in 2024, then increased by 2.09% to -$21.0 million in 2025, then soared by 53.04% to -$9.9 million in 2026.
• Business Quant data shows GYRE's Income towards Parent Company at -$9.9 million in Q1 2026, -$21.0 million in Q4 2025, and $5.9 million in Q3 2025.